新港生物医药科技

Xingang Biomedical Technology (Shanghai) Co., Ltd. (Xingang Biotech) is a Chinese biotechnology company focused on the research and development of novel antibody-drug conjugates (ADCs) and monoclonal antibodies for oncology and immunotherapy. Wholly founded and owned by Shanghai NewConcept Biomedical Science & Technology Limited (NewBio Therapeutics), the company leverages proprietary site-specific conjugation technologies to develop targeted cancer therapies. Its lead clinical candidate, NBT-508, is a humanized anti-CD79b monoclonal antibody-MMAE conjugate currently undergoing Phase I clinical trials in China for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Xingang Biotech collaborates with contract development and manufacturing organizations (CDMOs) such as TOT BIOPHARM (东曜药业) to advance its pipeline.